Dec 2, 2025 · Litfulo In June 2023, the FDA approved another JAK inhibitor, LITFULO® (ritlecitinib), for the treatment of severe alopecia areata in adults and adolescents ages 12 and …

Dec 23, 2024 · Discover how Litfulo (ritlecitinib), a newly FDA-approved treatment for severe alopecia areata, offers renewed hope for patients seeking effective hair regrowth solutions.

Safety Results from ALLEGRO No treatment differences between ritlecitinib 50 mg QD and placebo were observed in rates of serious adverse events, discontinuations due to adverse …

LITFULO (ritlecitinib) is a prescription medicine used to treat severe alopecia areata in adults and adolescents 12 years and older.

Jan 29, 2025 · Across subgroups, safety was similar. "The majority of ritlecitinib-treated patients with AA who met target clinical response based on scalp, eyebrow, or eyelash regrowth at …

Dec 1, 2025 · Description Ritlecitinib is used to treat severe alopecia areata (autoimmune disorder that causes patchy hair loss). This medicine is a Janus kinase 3 (JAK3) and tyrosine kinase …

Jun 27, 2023 · Litfulo is used to treat severe alopecia areata to reduce hair loss in adults and adolescents 12 years and older. It is an oral capsule that is taken once a day. Includes Litfulo …

Apr 24, 2024 · Ritlecitinib is an exciting new treatment; however, it is important to remember that it is for the treatment of severe alopecia areata only and will not work for other hair loss types …

Feb 18, 2025 · Litfulo emerges as a promising solution for those grappling with alopecia areata, a condition marked by hair loss linked to immune system misfires. This FDA-approved oral …

The most common side effects (≥1%) reported for LITFULO in clinical trials through 24 weeks of treatment were headache, diarrhea, acne, rash, urticaria, inflamed hair pores (folliculitis), …